Everolimus Toxicity in a Kidney Transplant Recipient Treated with Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir for Chronic Hepatitis C

AKIN M., Buldukoglu O. C., ADANIR H., Yalcinkaya T., YILMAZ V. T., YILDIRIM B., ...More

TURKISH JOURNAL OF NEPHROLOGY, vol.29, no.1, pp.82-83, 2020 (ESCI) identifier identifier

  • Publication Type: Article / Article
  • Volume: 29 Issue: 1
  • Publication Date: 2020
  • Doi Number: 10.5152/turkjnephrol.2020.3567
  • Journal Name: TURKISH JOURNAL OF NEPHROLOGY
  • Journal Indexes: Emerging Sources Citation Index (ESCI), Scopus, TR DİZİN (ULAKBİM)
  • Page Numbers: pp.82-83
  • Keywords: Everolimus, toxicity, chronic hepatitis C, ombitasvir/paritaprevir/ritonavir, DRUG-INTERACTIONS
  • Akdeniz University Affiliated: Yes

Abstract

The incidence of chronic hepatitis C virus (HCV) infection in kidney transplant recipients is 5%-15%, and HCV is an important risk factor for posttransplant kidney issues. Novel interferon-free regimens with direct-acting oral antiviral agents have extremely high response rates in solid organ transplant patients with HCV; however, drug-drug interactions, particularly with immunosuppressive agents, should be considered when deciding the treatment. Here we report a case of severe everolimus toxicity in a kidney transplant recipient receiving ombitasvir/paritaprevir/ritonavir and dasabuvir combination treatment.